Clinical Trials

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04487080 2026-04-22

MARIPOSA

1,074 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-04-22

MARIPOSA-2

776 enrolled 13 charts 2 FDA

870 enrolled 15 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01682083 2026-04-21

COMBI-AD

Phase 3 Completed

Dermatologic

Melanoma, Neoplasms

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03914612 2026-04-21

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04083235 2026-04-20

NAPOLI 3

Phase 3 Completed

770 enrolled 13 charts 2 FDA

Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT04404283 2026-04-20

ECHELON-3

239 enrolled 2 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03653507 2026-04-17

GLOW

507 enrolled 65 charts 2 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 2 FDA

Plasma cell

Smoldering Multiple Myeloma

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 2 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 3 FDA

Lymphoid

Hodgkin Disease

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 2 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Plasma cell

Multiple Myeloma

NCT04099251 2026-04-09

CheckMate76K

790 enrolled 18 charts 2 FDA

Dermatologic

Melanoma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 2 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 3 FDA

Breast

Breast Neoplasms

NCT02511106 2026-03-30

ADAURA

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma